Optimizing Method Development and Validation of Bioanalytical Assays for Challenging Chemical Constructs
This webinar will discuss the analytical challenges associated with the LC-MS bioanalysis of low molecular weight molecules (<200 amu) often associated with metabolomic measurements and analysis of biomarkers and metabolic products of drug biotransformations.
Agenda:
How the Properties of Low Molecular Weight Molecules Influence the Appropriate Bioanalytical Approach
- Hydrophilicity and Lipophilicity on extraction and separation conditions
- MS sensitivity, MS/MS fragments and opportunities to enhance response through assay conditions, derivatization
Case Studies Developing Assays Targeting Low Molecular Weight Species
- Examples of bioanalytical assays targeted toward measuring low molecular weight entities
Moderated by:
Scott Summerfield – Senior Director Pharmaceutical Metabolism at Pharmaron
Speakers
Hermes Licea-Perez – Scientific Director and Technology Leader at GSK
Dr. Hermes Licea Perez is the Scientific Director and Technology Leader in the Biomarker and Bioanalytical Platforms department at GSK, focusing on precision medicine. His selection as a GSK Fellow highlights his notable contributions to the analytical community. Dr. Licea Perez’s educational journey began in Cuba, followed by a Master of Science in Chemistry from Moscow State University and a PhD from Stockholm University. At GSK, his work focuses on method development and validation of pharmaceutical drugs using techniques such as protein precipitation, SPE, LLE, and chemical derivatization for LC (or SFC)-MS/MS detection. He enjoys developing challenging assays and has authored 40+ scientific publications on the bioanalysis of drugs and their metabolites. Dr. Licea Perez’s career at GSK allows him to contribute to advancements in precision medicine, improving patient outcomes and driving innovation.
Jing Lai, Ph.D. – Associate Director ADME at Pharmaron
Jing achieved her Doctorate degree from the China Agricultural University, major in veterinary pharmacology and toxicology in 2013. She has worked in the in vitro ADME department at Pharmaron for the last 9 years managing in vitro ADME screening projects and for the integrated services providing scientific ADME input and assay service to clients. Jing has broad experience in screening and delivery across numerous in vitro ADME assays including enzymes, transporters and permeability. CYP induction, CYP inhibition, nuclear receptor activation, non-CYP enzyme phenotyping, transporter and Currently Jing is leading the Pharmaron in vitro ADMET innovation team where her team is responsible for assay harmonization and optimization, and setting-up of new assay platforms.